NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

生物相似藥的全球市場 (2020年∼2027年)

Global Biosimilars Market, Size, Share, Opportunities and Forecast, 2020-2027

出版商 DataM Intelligence 商品編碼 982596
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
生物相似藥的全球市場 (2020年∼2027年) Global Biosimilars Market, Size, Share, Opportunities and Forecast, 2020-2027
出版日期: 2021年04月03日內容資訊: 英文 180 Pages
簡介

本報告提供全球生物相似藥市場相關分析,市場基本結構及最新形勢,整體市場趨勢預測 (今後8年份),各產品、各用途及各地區詳細趨勢,主要的推動及阻礙市場要素,市場競爭結構,主要企業的簡介、事業策略等相關調查。

目錄

第1章 全球生物相似藥市場:分析方法、範圍

第2章 全球生物相似藥市場:市場定義和概要

第3章 全球生物相似藥市場:摘要整理

第4章 全球生物相似藥市場:市場動態

  • 對市場的影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響力分析

第5章 全球生物相似藥市場:產業分析

  • 波特的五力分析
  • 專利分析
  • 法規分析

第6章 全球生物相似藥市場:各產品

  • 簡介
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各產品
    • 市場向心力指數:各產品
  • 單株抗體
    • 簡介
    • 市場規模 (以金額為準,2018∼2027年)、與前一年同期相比成長率 (YoY) (2019∼2027年)
  • 重組人體生長荷爾蒙(rhGH)
  • 胰島素
  • 抗凝固劑
  • 促血紅細胞生長素
  • 融合蛋白質
  • 顆粒細胞增生因子
  • 促濾泡素
  • 其他

第7章 全球生物相似藥市場:各用途

  • 簡介
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各用途
    • 市場向心力指數:各用途
  • 腫瘤
  • 慢性疾病/免疫疾病
  • 感染疾病
  • 造血系疾病
  • 其他

第8章 全球生物相似藥市場:各地區

  • 簡介
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各地區
    • 市場向心力指數:各地區
  • 北美
    • 簡介
    • 域內市場固有趨勢
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各產品
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各用途
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各國
  • 歐洲
  • 南美
  • 亞太地區
  • 中東、非洲

第9章 全球生物相似藥市場:競爭情形

  • 競爭方案
  • 企業策略分析
  • 組合的種類:比較分析
  • 市場定位/佔有率分析
  • 企業合併、收購 (M&A)的分析

第10章 企業簡介

  • Amgen Inc.
    • 企業概要
    • 產品的組合/概要
    • 近幾年趨勢
    • 財務分析:概要
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Biocon
  • Samsung Bioepis
  • Mylan NV
  • Celltrion
  • Biogen
  • Intas Pharmaceutical Ltd.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Global Biosimilars Market is segmented by Therapy Type (Recombinant Non-Glycosylated Proteins (Human growth hormone, Granulocyte colony-stimulating factor, Interferons, Insulin), Recombinant Glycosylated Proteins (Erythropoietin, Monoclonal antibodies, Follitropin)), by Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Others), by End User (Hospitals, Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview:

Biosimilar drugs are highly identical to approved biologic drugs. They possess similar medical properties in terms of potency, safety, and efficacy to original biologic products. High prevalence of chronic diseases such as diabetes, cancer, growth hormone deficiency, and anemia are expected to further fuel market expansion in the near future. As per a recent article, biosimilars are estimated to play a significant role in enhancing the public health issue by addressing the customer needs. The potential savings from the use of biosimilars is estimated to be around over USD 100 billion by the year 2020. Increase in demand for biosimilar drugs in order to reduce the healthcare cost will be one of the major markets boosting factors. In 2019, the Global Biosimilars market was USD XX million, with a XX% compound annual growth rate (CAGR) through 2027. According to a recent report, more than 40 biosimilars are under development, including approximately 20 biosimilars ready to be released into the market, and a significant number of biosimilars are in the pipeline.

Market Dynamics:

Increasing number of biosimilar drug approvals by the FDA

Increase in number of approved biosimilars due to greater clarity in the U.S. Food and Drug Administration (FDA) review process other than manufacturing and development process are expected to drive biosimilars market growth. For instance, in July 2018, the U.S. FDA introduced a Biosimilars Action Plan to encourage the development of biosimilars. This approval process encourages applicants to resolve patent disputes before launch of biosimilars. Moreover, the number of filed biosimilars applications has increased as manufacturers have become more comfortable with the complex regulatory and litigation schemes associated with filing a biosimilar application. For instance, according to the biosimilars update report by Amgen in 2019, As of January 2019, the US Food and Drug Administration (FDA) approved 17 biosimilars, out of which 7 products launched in 4 therapeutic areas.

However, high development cost of the biosimilar drug will be one of the major reasons impeding the adoption rates in under-developed and few developing countries. As per a recent research, it takes around 7 to 8 years and costs around USD 100 million to USD 250 million to develop a biosimilar. High cost related to biosimilar drugs development will continue to hinder market growth over the forecast timeframe.

Moreover, several manufacturing challenges for biosimilars that primarily arise due to biologics being far more structurally complex and more difficult to characterize, produce, and reproduce than most small-molecule drugs are also expected to restrain the market growth. A small variation in the manufacturing process can potentially alter the medicine's safety and efficacy.

Market Segmentation:

Monoclonal antibodies segment is predicted to hold prominent share in the global market of biosimilars

The global biosimilars market has been segmented by product type into monoclonal antibodies, recombinant human growth hormone (rhgh), insulin, anti-coagulants, erythropoietin, fusion proteins, granulocyte colony stimulating factor and follitropin among others. The monoclonal antibodies segment is expected to hold the highest market share in the year 2019. Increasing usage of biosimilar monoclonal antibodies that are cost effective and increasing number of product launches is expected to drive the market for monoclonal antibodies. For instance, in April 2020, Roche developed a serology test to detect antibodies in individuals who have been exposed to COVID-19. In April 2020, Lilly partnered with the National Institutes of Allergy and Infectious Diseases (NIAID) to study baricitinib as part of NIAID's Adaptive COVID-19 treatment clinical trial. NIAID, part of the National Institutes of Health (NIH), and Lilly progressed LY3127804, an investigational selective monoclonal antibody against Angiopoietin 2 (Ang2), to Phase 2 testing in pneumonia patients hospitalized with COVID-19.

Moreover, the oncology segment dominated the global market for biosimilars in terms of revenue in 2019. This is due to the high prevalence of cancer including lung, liver, colorectal, stomach, breast, and blood cancer.

Geographical Penetration:

North America is expected to dominate the biosimilars market

By geography, North America is expected to dominate the global biosimilars market in the year 2019, growing with a CAGR of xx% during the forecast period. U.S. dominated the North America Biosimilars market and was valued at USD XX million in the year 2019. U.S. accounted for highest market revenue share of XX% in the year 2019. There have been numerous licensing transactions and joint ventures in this industry which has improved the accessibility of the marketed biosimilars in the U.S. Owing to higher ability to provide higher returns than for small molecules or generic drugs, the industry is drawing interest in a wide spectrum of pharmaceutical companies. For instance, Amgen Inc., is fostering its product pipeline to become a powerhouse in the U.S. biosimilars market. The company has invested about USD 200 million in each of its 10 programs.

Competitive Landscape:

The global biosimilars market is highly fragmented. There is massive competition in the biosimilar market. With the presence of many domestic and also international market players. Most of the market players are adopting various growth strategies such as acquisitions, partnerships, new product launches to survive in the market. For instance, in 2018 Mylan NV  launched Hulio, a biosimilar to AbbVie's Humira (adalimumab).

COVID-19 Impact: COVID has positively impacted the biosimilars market

The spread of COVID-19 across the globe has positively impact the biosimilars market as there were many clinical trials being conducted. In April 2020, Lilly partnered with the National Institutes of Allergy and Infectious Diseases (NIAID) to study baricitinib as part of NIAID's Adaptive COVID-19 treatment clinical trial. NIAID, part of the National Institutes of Health (NIH), and Lilly progressed LY3127804, an investigational selective monoclonal antibody against Angiopoietin 2 (Ang2), to Phase 2 testing in pneumonia patients hospitalized with COVID-19. The Pfizer initiative, the COVID-19 Therapeutics Accelerator, will assess, identify and scale-up treatments to make products available and affordable for vulnerable communities. It will screen thousands of safety-related compounds and consider new investigational compounds and monoclonal antibodies. 

Recent Developments:

In March 2020, Pfizer Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg which is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor (NGF) inhibitors.

In 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of metastatic Merkel cell carcinoma (MCC), a rare disease.

Why Purchase the Report?

Understand the current market scenario and viability of Global biosimilars over the forecast period.

Visualize the composition of the global biosimilars market in terms of product and by application to identify major players, growth potential, and market strategies

Identify the key regulations prevailing in the market and understand their impact on the market over the forecast period

Understand the key business factors such as market competition, product pricing, new product developments, and patent filings pertaining in the market

What we offer?

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Excel data sheet with valuable data points of the Global biosimilars market - Regional and Country level segmentation

Product mapping in excel for the key products of all major market players

Market Share Analysis covering business revenues ($) and revenue share (%) of key market players

Target Audience:

Biosimilars Manufacturers and Suppliers

Biosimilars Industry Players

Suppliers/Buyers

Emerging Companies

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Table of Contents

Table of Contents

Biosimilars Market -Scope and Methodology

Research Methodology

Scope of the Market

Biosimilars Market -Key Trends and Developments

Biosimilars Market - Executive Summary

Market Snippet by Product

Market Snippet by Application

Biosimilars Market-Market Dynamics

Market impacting factors

Drivers

Increasing number of biosimilar drug approvals by the FDA

Increasing demand for biosimilar drugs due to their cost effectiveness

Restraints

High development cost of the biosimilar drug

Opportunities

Impact analysis

Biosimilars Market - Industry Analysis

Porter's five forces analysis

Patent Analysis

Regulatory Analysis

Biosimilars Market - By Product

Introduction

Market size analysis, and y-o-y growth analysis (%), By Product segment

Market attractiveness index, By Product segment

Monoclonal Antibodies

Introduction

Market Size Analysis, US$ Million, 2018-2027 And Y-O-Y Growth Analysis (%), 2019-2027  

Recombinant Human Growth Hormone (rhGH)

Insulin

Anti-coagulants

Erythropoietin

Fusion Proteins

Granulocyte Colony Stimulating Factor 

Follitropin

Others

Biosimilars Market - By Application

Introduction

Market size analysis, and y-o-y growth analysis (%), By Application Segment

Market attractiveness index, By Application Segment

Oncology

Introduction

Market Size Analysis, US$ Million, 2018-2027 And Y-O-Y Growth Analysis (%), 2019-2027  

Chronic and Immune Diseases

Infectious Diseases

Blood Disorders

Others

Biosimilars Market - By Region

Introduction

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key region-specific dynamics

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country

U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country

Germany

U.K.

France

Italy

Spain

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country

Brazil

Argentina

Chile

Rest of South America

Asia Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country

China

India

Japan

Australia & New Zealand

Rest of Asia Pacific

The Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product

Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

Biosimilars Market - Competitive Landscape

Competitive scenario

Competitor strategy analysis

Comparative type portfolio analysis

Market positioning/share analysis

Mergers and acquisitions analysis

Company Profiles

Amgen Inc.

Company Overview

Type Portfolio and Description

Key Highlights

Financial Overview

Teva Pharmaceutical Industries Ltd.

Novartis AG

Pfizer Inc.

Biocon

Samsung Bioepis

 Mylan NV

Celltrion

Biogen

Intas Pharmaceutical Ltd. (*List Is Not Exhaustive)

Biosimilars Market - Premium Insights

Biosimilars Market - DataM

Appendix

About us and services

Contact us